{
    "title": "Understanding Clinicians’ Perceptions – Assessing Physicians’ Awareness and Perception of S-Amlodipine",
    "sections": [
        {
            "section": "Awareness & Understanding",
            "questions": [
                {
                    "id": 1,
                    "question": "How familiar are you with the concept of chirality in drug molecules?",
                    "options": [
                        "Very familiar",
                        "Somewhat familiar",
                        "Heard of it, but not in detail",
                        "Not familiar at all"
                    ]
                },
                {
                    "id": 2,
                    "question": "How well do you understand the difference between S-Amlodipine and racemic Amlodipine?",
                    "options": [
                        "Clearly understand both clinical and pharmacological differences",
                        "Aware of the difference, but unsure of clinical significance",
                        "Not well aware",
                        "Never considered the difference"
                    ]
                }
            ]
        },
        {
            "section": "Clinical Beliefs & Perceptions",
            "questions": [
                {
                    "id": 3,
                    "question": "Please rate your agreement with the following statements regarding S-Amlodipine on a 1 to 5 scale (1 = Strongly Disagree, 5 = Strongly Agree).",
                    "scale": [
                        1,
                        2,
                        3,
                        4,
                        5
                    ],
                    "statements": [
                        "S-Amlodipine offers better tolerability than racemic Amlodipine",
                        "S-Amlodipine reduces the risk/incidence of pedal edema",
                        "S-Amlodipine provides comparable or better BP control than the racemic version",
                        "I feel more confident prescribing S-Amlodipine to elderly patients",
                        "S-Amlodipine enhances patient compliance due to a better safety profile"
                    ]
                }
            ]
        },
        {
            "section": "Prescribing Behaviour",
            "questions": [
                {
                    "id": 4,
                    "question": "Do you currently prescribe S-Amlodipine in your clinical practice?",
                    "options": [
                        "Yes, regularly",
                        "Occasionally",
                        "Rarely",
                        "Never"
                    ]
                },
                {
                    "id": 5,
                    "question": "In which patient groups do you consider S-Amlodipine over racemic Amlodipine?",
                    "options": [
                        "Patients prone to pedal edema",
                        "Elderly patients",
                        "Patients with poor tolerance to racemic Amlodipine",
                        "Long-term therapy cases",
                        "Newly diagnosed hypertensives",
                        "I do not differentiate currently"
                    ]
                },
                {
                    "id": 6,
                    "question": "Have you ever switched a patient from racemic Amlodipine to S-Amlodipine due to tolerability issues (e.g., pedal edema)?",
                    "options": [
                        "Yes, frequently",
                        "Occasionally",
                        "Rarely",
                        "Never"
                    ]
                }
            ]
        },
        {
            "section": "Barriers & Drivers",
            "questions": [
                {
                    "id": 7,
                    "question": "What do you consider the main barriers to wider adoption of S-Amlodipine?",
                    "options": [
                        "Higher cost",
                        "Lack of awareness about chirality benefits",
                        "Limited clinical evidence",
                        "Familiarity/comfort with racemic brands",
                        "Lack of availability"
                    ]
                },
                {
                    "id": 8,
                    "question": "What would make you more likely to prescribe S-Amlodipine in your routine practice?",
                    "options": [
                        "Stronger comparative clinical evidence",
                        "Patient demand or feedback",
                        "Better affordability",
                        "More peer recommendations",
                        "More CME/scientific content"
                    ]
                }
            ]
        },
        {
            "section": "Fixed-Dose Combination: Telmisartan + S-Amlodipine",
            "questions": [
                {
                    "id": 9,
                    "question": "How effective is Telmisartan + S-Amlodipine combination in achieving BP control within 4 weeks?",
                    "options": [
                        "Very effective",
                        "Moderately effective",
                        "Slightly effective",
                        "Not effective"
                    ]
                },
                {
                    "id": 10,
                    "question": "For which patient profiles would you specifically consider Telmisartan + S-Amlodipine?",
                    "options": [
                        "Patients prone to pedal edema",
                        "Patients requiring long-term therapy",
                        "Elderly patients"
                    ]
                },
                {
                    "id": 11,
                    "question": "Do you switch patients from Telmisartan + racemic Amlodipine to Telmisartan + S-Amlodipine due to side effects (e.g., pedal edema)?",
                    "options": [
                        "Yes, frequently",
                        "Occasionally",
                        "Rarely",
                        "Never"
                    ]
                },
                {
                    "id": 12,
                    "question": "What would be the biggest driver for you to shift from Telmisartan + racemic Amlodipine to Telmisartan + S-Amlodipine?",
                    "options": [
                        "Better tolerability (e.g., less edema)",
                        "Stronger clinical evidence",
                        "Better efficacy data",
                        "Improved patient compliance",
                        "Greater affordability for patients"
                    ]
                },
                {
                    "id": 13,
                    "question": "What barriers do you see in prescribing Telmisartan + S-Amlodipine more widely?",
                    "options": [
                        "Cost compared to racemic combinations",
                        "Limited awareness of chirality advantage",
                        "Lack of strong comparative evidence",
                        "Comfort with existing racemic brands",
                        "No significant barriers"
                    ]
                }
            ]
        }
    ]
}